Navigation Links
AMA Rejects PBS 'Measure and Share' Proposals

The AMA Federal Council has rejected outright Pharmaceutical Benefits Scheme (PBS) 'measure and share' proposals, which are currently being pushed by some medical groups. //

AMA President, Dr Mukesh Haikerwal, said today that any PBS savings derived from changed prescribing patterns must be re-invested back into the PBS.

'Evidence-based prescribing information and other education strategies, including details of comparative prescribing patterns, contribute to improvements in the quality use of medicines,' Dr Haikerwal said.

The AMA supports the education activities of the National Prescribing Service, particularly at the local level, which include:

  • The provision of independent, evidence-based information regarding best practice prescribing and use of medicines


  • The development and implementation of opportunities for GPs to participate in peer review of prescribing


  • The development and dissemination of public education regarding quality use of medicines


    • Dr Haikerwal said that rather than pursuing 'measure and share' programs, the AMA wants the Government to boost National Prescribing Service resources and funding to allow them to broaden the range and reach of their services.

    'The AMA emphasises that any PBS savings derived from Quality Use of Medicines activities must be retained within the PBS to benefit all Australians.

    'There should never be any doubt that prescribing is best practice and patient-centred, and there are no ulterior motives attached to treatments prescribed,' Dr Haikerwal said.
    '"/>




    Page: 1

    Related medicine news :

    1. Games Event Rejects Prior Transplant Patient
    2. Court Rejects Case of Negligence by Disabled Children against the Doctors
    3. Apex Consumer Court Rejects Rs 143 Cr Medical Negligence Claim
    4. Spanish Fashion Show Rejects Five Models as too Thin
    5. Single Women and Lesbians To Enjoy Full Rights in Donor Child Proposals
    6. Tuberculosis Experts Outline Proposals to Speed Up Drug Development
    Post Your Comments:
    (Date:9/5/2008)...Study finds risk is greatest for those overweight ...HealthDay News) -- Almost half of all American adu... 85, and their odds increase if they are obese in ...k of having the painful condition increased as his...he University of North Carolina at Chapel Hill stu...
    (Date:9/5/2008)...But officials say patients taking meds on Web site... , FRIDAY, Sept. 5 (HealthDay News) -- The U.S. ...n its Web site drugs being evaluated for potential...a drug appears on a quarterly report, it means we ...a safety problem that requires further evaluation,...
    (Date:9/5/2008)... HOUSTON - Lung cancer risk prediction models are...ace and by measuring DNA repair capacity, accordin...University of Texas M. D. Anderson Cancer Center i...ber issue of Cancer Prevention Research . , In ...earchers found unique results based on increased e...
    (Date:9/4/2008)... WHITE PLAINS, N.Y., Sept. 5 /PRNewswire/ -- A ...ing physical, mental and emotional status of,men, ...ychological and,medical needs will take place Wedn...program under the auspices of members of the Westc...ure talks by Marianne J. Legato,M.D. and Lionel T...
    Breaking Medicine News(10 mins):Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3
    ...predict risk of surgery. Lens as thick as two stra...re developing after coronary bypass surgery. The m...end to re-block, risking heart attack and requirin...through the artery could be detected at an early s...
    ... for smallpox, which kills about 30% of its victim... vaccine within days of exposure can protect again...e up to 90 million doses of decades-old smallpox v...the supplies if they are still effective against t...
    ...g tamoxifen does not damage the brains of elderly ... such treatment, recent study has revealed. Accord... on the brain to oestrogen, which has been linked ...n //against cognitive decline. The researchers use...
    ...cation Plavix (clopidogrel bisulfate) received US ...cute coronary syndrome. People with acute coronary...ally because they have unstable angina, or heart d...o 1.4 million Americans experience acute coronary ...
    Other Medicine News:
    (Date:9/5/2008)... -- When Michigan,s first chronic,wasting disease ...arm in,Kent County, state and federal officials sh...roperty and began the process of testing them for ...ng statement on the negative CWD,test results on t... deer farm industry today received welcome news wh...
    (Date:9/5/2008)...re-USNewswire/ -- A team of,researchers at West Vi...rom,India and Pakistan take on the habits of their...te cancer among male immigrants and breast cancer,...r develop due to many reasons, but,environmental f...ncers,",said Jame Abraham, M.D., medical director ...
    (Date:9/4/2008)...ime PCR testing for the diagnostic ...4 /- The U.S. Food & Drug,Administrat...) HBV Test,the first assay for quantitating Hepat...s Roche,s real-time PCR technology to quantify the...ood. Doctors may use viral load,testing results to...
    (Date:9/4/2008)...Newswire/ -- Axentis Pharma AG has,initiated a cli...erability,of a new therapeutic formulation for the... fibrosis patients. The new formulation allows an,...ctly to the site of,infection. The forthcoming tri...doses of the new drug. Initial results are expecte...
    Breaking Medicine Technology:Deer Farm Industry in Michigan Issues Statement on the Negative CWD Test Results at Kent County Deer Farm 2Deer Farm Industry in Michigan Issues Statement on the Negative CWD Test Results at Kent County Deer Farm 3Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4BioElectronics CEO Andrew Whelan 3A Positioning the Company for Growth During 2008 and Beyond 16676 1BioElectronics CEO Andrew Whelan 3A Positioning the Company for Growth During 2008 and Beyond 16676 2BioElectronics CEO Andrew Whelan 3A Positioning the Company for Growth During 2008 and Beyond 16676 3BioElectronics CEO Andrew Whelan 3A Positioning the Company for Growth During 2008 and Beyond 16676 4EXL Announces Appointment of Rembert de Villa as Head of Transformation Services 4564 1EXL Announces Appointment of Rembert de Villa as Head of Transformation Services 4564 2EXL Announces Appointment of Rembert de Villa as Head of Transformation Services 4564 3EXL Announces Appointment of Rembert de Villa as Head of Transformation Services 4564 4Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 1Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 2Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 3Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology 1759 4KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 1KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 2KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 3KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 4KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 5KV Begins Shipping Evamist 28TM 29 to Wholesalers 16672 6
    ...ny to Proceed with Development Program for Oral Co... Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, I...inary results from a,clinical trial of ALKS 29 in ..., the company plans to move forward with its,devel...t alcohol,dependence. ALKS 29 is a combination of ...
    ...Data from Phase III Intergroupe Francophone du Mye..., Mass., July 02, 2007 /PRNewswire-FirstCall/ --,M...t new data were,presented on the comparative Phase...rapy in newly diagnosed multiple myeloma (MM),pati...splantation,(SCT), the VELCADE based therapy produ...
    Other Medicine Technology:Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 2Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 3Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6
    Stryker autoclavable pediatric laparoscopes provide equivalent brightness and resolution along with the unparalleled durability found in larger laparoscopes.
    The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s
    Bactron IV is designed for high volume, yet requires far less bench space than expected for its capacity and performance features.
    Designed for larger laboratories or research applications, the Concept 1000 boasts some very unique features.
    Medicine Products: